When will the FDA approve Compass Pathways' COMP360 Psilocybin?
As of Fri, 20 Nov 2026 07:30:49 UTC, Kalshi traders price Before 2028 (91.0%), Before October 2027 (88.0%), Before July 2027 (84.0%). The market has $28K in volume and closes on Sat, 01 Jan 2028.
Updated:
Current odds
| Outcome | Chance | Yes price | No price |
|---|---|---|---|
| Before 2028 | 91.0% | 91.0¢ | 9.0¢ |
| Before October 2027 | 88.0% | 88.0¢ | 12.0¢ |
| Before July 2027 | 84.0% | 84.0¢ | 16.0¢ |
| Before Mar 1, 2027 | 64.0% | 64.0¢ | 36.0¢ |
| Before Jan 1, 2027 | 23.0% | 23.0¢ | 77.0¢ |
Market details
- Venue: Kalshi
- Volume: $28K
- Liquidity: $28K
- Closes:
Sources
Related markets
- Will the FDA approve retatrutide?
- Tesla Optimus released this year?
- How many launches will SpaceX have this year?
- When will any company achieve AGI?
- How many launches will SpaceX have in November?
- When will Apple release the iPhone 18?
More markets like this
- When will the FDA approve Intellia Therapeutics' lonvo-z?
- Will the FDA approve a cure for Type 1 diabetes before 2033?
- Will the FDA approve CagriSema?
- Will the FDA approve VERVE-102?
- When will the first 2028 Republican primary debate be?
- When will the first listed Democrat announce a 2028 presidential run?
- When will the first listed Republican announce a 2028 presidential run?
- When will the first useful quantum computer be developed?
A price on DOXA is the market-implied probability of an outcome on the venue that lists it. It is what traders are paying, not a forecast made by DOXA, and it is not investment advice. How DOXA shows prices · Terms of Use
DOXA is a liquidity aggregator for prediction markets that compares odds and depth across Polymarket, Kalshi and others and routes each trade for best execution with an AI assistant.